Inovio completes enrollment in late-stage of VGX-3100 in HPV; shares up 5% premarket - Seeking Alpha

Inovio completes enrollment in late-stage of VGX-3100 in HPV; shares up 5% premarket  Seeking Alpha

Inovio Pharmaceuticals (INO) has completed target enrollment of 198 participants for its Phase 3 registration trial ("REVEAL 1") of VGX-3100, a DNA-based i.